Stockreport

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

Neuropace, Inc.  (NPCE) 
PDF -- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) ---- 18-month data show a 77% median reduction in general [Read more]